Portrait Our objective is to develop methods to treat Calcifying Nanoparticles (CNPs), and by so doing find more effective approaches to the diseases associated with them.
Pharmaceutical Drug Discovery Our drug discovery and development efforts focus on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. We are narrowly focused on new combinations of well-known drugs that have been shown to eradicate CNPs. Our business strategy is to develop and license compounds to address unmet needs of patients in the cardiovascular and urological disease markets.
Diagnostics Our diagnostics division develops in vitro diagnostic products and laboratory services that are used worldwide.
In Vitro Diagnostics Kits and Reagents We offer IVD kits and reagents for detection of Calcifying Nanoparticles.
Clinical Laboratory Services We provide specialized clinical laboratory testing services to clinicians, hospitals, and laboratories. We specialize in advanced technologies for detecting and characterizing Calcifying Nanoparticles in human samples. Nanobac OY Clinical Laboratory in Finland is fully accredited by government regulatory agencies.
BioAnalytical Services We work with partners to develop methods for detecting and eliminating CNPs from raw materials or production substrates. Our contamination control program focuses on decontaminating host cell lines, animal and human derived materials, raw materials, diagnostic procedures and downstream processes.
Top
Contact
Print version
PDF version
Recommend company
